Abstract
The purpose of this study was to determine the maximum tolerated dose (MTD) of docetaxel based induction and concomitant chemoradiotherapy (CRT) after using the FHX platform (5 = 5-FU, H = hydroxyurea, X = Radiation). Patients with Stage III/IV locally advanced HNSCC were enrolled. Induction chemotherapy (carboplatin/docetaxel) was followed by 5 cycles of concomitant docetaxel based CRT. No DLTs were observed in dose levels 1/2 for induction and CRT. Dose level 2 was expanded. The overall survival CR rate after CRT was 79 percent. Median overall (OS) has not been reached and 2-year OS is 80.7 percent. The recommended Phase II dose of docetaxel with FHX CRT is 25 mg/m2 and 35 mg/m2 in combination with carboplatin induction (AUC = 6).
Original language | English (US) |
---|---|
Pages (from-to) | 435-444 |
Number of pages | 10 |
Journal | Cancer Investigation |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Sep 2007 |
Externally published | Yes |
Keywords
- 5-FU
- Chemoradiotherapy
- Docetaxel
- Hydroxyurea
- Induction Chemotherapy
- Locally Advanced Head and Neck Cancer
- Phase I
ASJC Scopus subject areas
- Oncology
- Cancer Research